Early prostate cancer: Is there a need for new treatment options?

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 2, 2003, Pages 105-116

  Klimberg, I ^a   Locke, D R ^a   Madore, R A ^a   Smith, W W ^a  

^a Urology Center of Florida   (United States)

Author keywords

Adjuvant; Early prostate cancer; Hormonal therapy; Neoadjuvant

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; HEALTH CARE COST; HIGH INTENSITY FOCUSED ULTRASOUND; HORMONAL THERAPY; HUMAN; MINIMALLY INVASIVE SURGERY; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; ECONOMICS; INCIDENCE; MALE; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

COMBINED MODALITY THERAPY; HEALTH CARE COSTS; HUMANS; INCIDENCE; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 0042887195     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00211-9     Document Type: Article

References (94)

1. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate cancer trends 1973-1995, Seer Program, Bethesda: National Cancer Institute, NIH Pub. No. 99-4543, 1999.
2. Brasso K, Friis S, Kjaer SK, Jorgensen T, Iversen P. Prostate cancer in Denmark: a 50-year population based study. Urology 1998;51:590-4.
3. Levi F, Ia Vecchia C, Randimbison L, Erler G, Te VC, Francheschi S. Incidence, mortality and survival from prostate cancer in Vaud and Neuchatel, Switzerland, 1974-1994. Annal Oncol 1998;9:31-5.
4. Murphy M, Johnston C, Whelan P, Rider L, Lloyd SN. Changing trends in prostate cancer. BJU Int 1999;83:786-91.
5. Post PN, Stockton D, Davies TW, Coebergh JW. Striking increase in incidence of prostate cancer in men aged <60 years without improvement in prognosis. Br J Cancer 1999;79:13-7.
6. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series. Part 1: Interpreting trends in prostate cancer. Evidence of the effect of screening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst 1999;91:1017-24.
7. Potosky AL, Miller BA, Albertson PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
8. Post PN, Straatman H, Kiemeney LA, Coebergh JW. Increased risk of fatal prostate cancer may explain the rise in mortality in The Netherlands. Int J Epidemiol 1999;28:403-8.
9. Mettlin C. Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974-1993. Prostate 1997;32:221-6.
10. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1679-84.
11. Greenlee RT, Hill-Harmon M-B, Murray T, Thun M. Cancer Statistics 2001. CA Cancer J Clin 2001;51:15-36.
12. Albertsen PC. Decreasing prostate cancer mortality in the US. Is the value of screening already proven? Renal Bladder Pros Cancer 1999;11:85-94.
13. Dearnaley DP, Kirby RS, Kirk D, Malone P, Simpson RJ, Williams G. Diagnosis and management of early prostate cancer. Report of a British Association of Urological Surgeons Working Party. BJU Int 1999;83:18-33.
14. Wilt TJ. Prostate carcinoma practice patterns. Cancer 2000;88:1277-81.
15. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999;38:83-91.
16. Boer R, Schroeder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate 1999;40:130-4.
17. de Koning HJ, Auvinen A, Berenguer SA, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002;97:237-44.
18. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 1995;154:2144-8.
19. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998;160:2418-24.
20. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999;49:282-96.
21. Thorpe AC, Cleary R, Coles J, Vernon S, Reynolds J, Neal DE. Deaths and complications following prostatectomy in 1400 men in the northern region of England. Northern Regional Prostate Audit Group. Br J Urol 1994;74:559-65.
22. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433-8.
23. Lai S, Lai H, Krongrad A, Roos BA. Overall and disease-specific survival after radical prostatectomy: geographic variation. Urology 2001;57:504-9.
24. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
25. Aus G, Hugosson J, Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995;154:460-5.
26. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 1997;12:299-305.
27. Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate 1999;40:261-8.
28. Campbell T, Blasko J, Crawford D, et al. Clinical staging of prostate cancers: reproducibility and clarification of issues. Int J Cancer 2001;96:198-209.
29. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment Panel of the NHS executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997;79(Suppl 3):1-32.
30. Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after radiotherapy for prostate cancer: review. Int J Radiat Oncol Biol Phys 2002;52:681-93.
31. Roach M, Lu J, Pilepich MV, et al. Long-term survival after radiotherapy alone: radiation oncology group prostate cancer trials. J Urol 1999;161:864-8.
32. Chuba PJ, Moughan J, Forman JD, Wen J, Hanks G. The 1989 patterns of care study for prostate cancer: five-year outcomes. Int J Radiat Oncol Biol Phys 2001;50:325-34.
33. Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA. Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better? Int J Radiat Oncol Biol Phys 2001;51:1200-8.
34. Hafez KS, Miller DC, Staskon F, Montie JE, Wei JT. Increasing role of brachytherapy in the management of prostate cancer: the National Cancer Data Base experience. J Urol 2002;167(suppl 4):342 [abstr 1356].
35. Lee WR, McQuellon RP, Case LD, deGuzman AF, McCullough DL. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol 1999;162:403-6.
36. Blasko JC, Mate T, Sylvester JE, Grimm PD, Cavanagh W. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002;12:81-94.
37. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol 1999;162:421-6.
38. Brausi M, Palladini PD, Latini A. "Watchful waiting" for clinically localized prostate cancer: long term results. Eur Urol 1996;30(Suppl 2):225 [abstr 833].
39. Johansson J-E, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467-71.
40. Adolfsson J. Radical prostatectomy, radiotherapy or deferred treatment for localized prostate cancer. Cancer Surv 1999;23:141-8.
41. Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6.
42. Donovan JL, Frankel SJ, Faulkner A, Selley S, Gillatt D, Hamdy FC. Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. BMJ 1999;318:299-300.
43. Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6.
44. Clark JA, Rieker P, Propert KJ, Talcott JA. Changes in quality of life following treatment for early prostate cancer. Urology 1999;53:161-8.
45. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A pre-operative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Nat Cancer Inst 1998;90:766-71.
46. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathologic stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
47. Wei JT, Zhang Z, Barnhill SD, Madyastha KR, Zhang H, Oesterling JE. Understanding artificial neural networks and exploring their potential applications for the practising urologist. Urology 1998;52:161-72.
48. Mattfeldt T, Kestler HA, Hautman R, Gottfried HW. Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study. BJU Int 1999;84:316-23.
49. Guilloneau B, Cathelineau X, Barret E, Rozet F, Vallancien G. Laparoscopic radical prostatectomy: technical and early oncological assessment of 40 operations. Eur Urol 1999;36:14-20.
50. Guilloneau B, Vallancien G. Laparoscopic radical prostatectomy: initial experience and preliminary assessment after 65 operations. Prostate 1999;39:71-5.
51. Klein EA, Kupelian PA, Tuason L, Levin HS. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. Urology 1998;51:766-73.
52. Guillonneau B, Rozet F, Cathelineau X, et al. Perioperative complications of laparoscopic radical prostatectomy: the Montsouis 3-year experience. J Urol 2002;167:51-6.
53. Rassweiller J, Sentker L, Seemann O, Hatzinger M, Rumpelt HJ. Laparoscopic radical prostatectomy with the Heilbronn technique: an analysis of the first 180 cases. J Urol 2001;166:2101-8.
54. Bollens R, Vanden Bossche M, Roumeguere T, et al. Extraperitoneal laparoscopic radical prostatectomy. Results after 50 cases. Eur Urol 2001;40:65-9.
55. 3. Eur Urol 2000;38:64-73.
56. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. BMJ 1999;353:267-72.
57. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostatic cancer. J Clin Oncol 1999;17:517-22.
58. Slater JD, Rossi CJ, Yonemoto LT, et al. Conformal proton therapy for early-stage prostate cancer. Urology 1999;53:978-84.
59. Kupelain PA, Reddy CA, Willoughby TR. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per faction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001;51:988-93.
60. Long JP, Bahn D, Lee F, et al. Five-year retrospective multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57:518-23.
61. Onik G. Image-guided prostate cryosurgery: state of the art. Cancer Control 2001;8:522-31.
62. Beerlage HP, Thuroff S, Debruyne FM, Chaussy C, de la Rosette JJ. Transrectal high-intensity focused ultrasound using the ablatherm device in the treatment of localized prostate carcinoma. Urology 1999;54:273-7.
63. Zlotta AR, Djavan B, Matos C, et al. Percutaneous transperineal radiofrequency ablation of prostate tumor: safety, feasibility and pathologic effects on human prostate cancer. Br J Urol 1998;81:265-75.
64. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998;159:357-64.
65. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993;42:283-91.
66. Messing E, Manola J, Sarodsy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
67. Bono AV, Pagano F, Montironi R, et al. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study. Urology 2001;57:117-21.
68. Wirth M, Frohmüller H, Marx F, et al. Adjuvant antiandrogenic treatment after radical prostatectomy in stage C prostate cancer-preliminary results of a randomized controlled multicenter trial. Urology 1997;157:335 [abstr 1308].
69. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy-report of RTOG protocol 85-31. J Clin Oncol 1997;15:1013-21.
70. Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 1999;35(Suppl 1):23-6.
71. Zeitman AL, Prince EA, Nakfoor BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology 1997;49:74-83.
72. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
73. Prayer-Galetti T, Zattoni F, Capizzi A, Dal Moro F, Pagano F. Disease-free survival in patients with pathological "C Stage" prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur Urol 2000;38:504 [abstr 48].
74. Granfors T, Modig H, Damber J-E, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for non-metastatic prostate cancer with or without pelvic lymph node involvement. A prospective randomized study. J Urol 1998;159:2030-4.
75. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
76. Bolla M, Collette L, Gonzalez D, et al. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy-a phase III EORTC study. Eur J Cancer 1999;35(Suppl 4):S82.
77. Lawton C, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
78. Hanks GE, Lu J, Machtay M, et al. RTOG protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 2000;19:327a [abstr 1284].
79. See WA, McLeod DG, Iversen P, Wirth M. Bicalutamide Early Prostate Cancer program. Demography. Urol Oncol 2001;6:43-7.
80. See WA, McLeod D, Iversen P, et al. Bicalutamide 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002;168:429-35.
81. Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000;164:1465-72.
82. Schulman CC, DeBruyne FMJ, Forster G, et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol 2000;38:706-13.
83. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002;167:112-6.
84. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-6.
85. Laverdiere J, Gomes JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-52.
86. Meyer F, Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 1999;162:2024-8.
87. Eisenberger MA, Walsh PC. Early androgen deprivation for prostate cancer? N Engl J Med 1999:341 [editorial].
88. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154-79.
89. Mayer FJ. Future trends in the incidence and management of prostate cancer. West J Med 1994;160:380-1.
90. Beemsterboer PMM, de Koning HJ, Birnie E, van der Maas PJ, Schroder FH. Advanced prostate cancer: course, care and cost implications. Prostate 1999;40:97-104.
91. Taplin SH, Barlow W, Urban N. Stage, age, comorbidity and direct costs of colon, prostate and breast cancer. J Natl Cancer Inst 1995;87:417-26.
92. Brasso K, Friis S, Juel K, Jorgensen T, Iversen P. The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: a population based registry study. J Urol 2000;163(Suppl 4):1150-4.
93. Executive NHS. Burdens of disease. A discussion document. London: Department of Health, 1996.
94. Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M, Brochon D. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer 2001;37:1768-74.